How does CAR T cell therapy work?

CAR-T is a form of immunotherapy recently approved for the treatment of myeloma in the United States and Europe. While the process of manufacturing and administrating this treatment as well as side effects can be challenging, results of clinical trials have been promising in myeloma.
This video explains how CAR-T cell therapy works.

[@tiff1316]

In the description, it is mentioned that CAR-T is recently approved. Can I please ask when this was approved in the US and Europe and where I can find the sources for this? Love this video- Thank you so much!

[@MyelomaPatientsEurope]

Hello! thank you for your feedback on this video 😊 there are two CAR-T approved drugs, idecabtagene vicleucel in US and Europe and cilta-cel that was approved by the US Food and Drug Administration (FDA) a couple of days ago. Please, find below some information about these drugs: • Idecabtagene vicleucel: www.mpeurope.org/2021/03/31/the-u-s-food-and-drug-administration-fda-approves-the-first-anti-bcma-car-t-cell-therapy-for-myeloma-idecabtagene-vicleucel-abecma • Cilta-cel: www.mpeurope.org/2022/03/02/fda-approves-cilta-cel-for-relapsed-or-refractory-myeloma/ Drug approvals and reimbursements are different processes and there are several challenges we face in making CAR-T therapies widely available in Europe. Should you need more information, please, contact us at [e-mail]